Abstract:Brain arteriovenous malformations (AVMs) are a significant cause of intracerebral hemorrhage in children and young adults. Currently, one third of patients have no viable treatment options. Vascular targeting agents (VTAs) are being designed to deliver pro-thrombotic molecules to the abnormal AVM vessels for rapid occlusion and cure. This study assessed the efficacy of a pro-thrombotic VTA targeting phosphatidylserine (PS) in a radiation-primed AVM animal model. The model AVM was surgically created in rats by anastomosis of the left external jugular vein to the adjacent common carotid artery. After 6 weeks, the AVM was irradiated (20 Gy) using gamma knife surgery (GKS). A PS-targeting VTA was created by conjugation of annexin V with human thrombin and administered intravenously 3 weeks post-GKS or sham. Unconjugated thrombin was used as a non-targeting control. AVM thrombosis and occlusion was monitored 3 weeks later by angiography and histology. Preliminary experiments established a safe dose of active thrombin for systemic administration. Subsequently, a single dose of annexin V–thrombin conjugate (0.77 mg/kg) resulted in angiographic AVM occlusion in sham (75%) and irradiated (63%) animals, while non-targeted thrombin did not. Lowering the conjugate dose (0.38 mg/kg) decreased angiographic AVM occlusion in sham (13%) relative to irradiated (80%) animals (<em class="EmphasisTypeItalic">p</em> = 0.03) as did delivery of two consecutive doses of 0.38 mg/kg, 2 days apart (sham (0%); irradiated (78%); <em class="EmphasisTypeItalic">p</em> = 0.003). These findings demonstrate efficacy of the PS-targeting VTA and the feasibility of a vascular targeting approach for occlusion of high-flow AVMs. Targeting specificity can be enhanced by radiation–sensitization and VTA dose modification.

Defining the Role of Oral Pathway Inhibitors as Targeted Therapeutics in Arteriovenous Malformation Care

Arteriovenous Malformations—Current Understanding of the Pathogenesis with Implications for Treatment

Current trends, molecular insights, and future directions toward precision medicine in the management of pediatric cerebral arteriovenous malformations

Extracranial Arteriovenous Malformations: from Bedside to Bench

MEK inhibitors for the treatment of extracranial arteriovenous malformations

Targeting the microenvironment in the treatment of arteriovenous malformations

A Practical Guide for Diagnosis and Treatment of Arteriovenous Malformations in the Oral and Maxillofacial Region.

Occlusion of Animal Model Arteriovenous Malformations Using Vascular Targeting

Advancement of genetics and target therapy of extracranial arteriovenous malformation

Endovascular treatment of cranial arteriovenous malformations and dural arteriovenous fistulas

Targeted therapies for vascular malformations

High-Flow Arteriovenous Malformations: Treatment Using a Venous Approach

Research Progress on Targeted Drugs for Vascular Malformations

Most Promising Approaches to Improve Brain AVM Management: ARISE I Consensus Recommendations

Evaluation of Surgical Treatment for Intracranial Arteriovenous Malformations

A non-genetic model of vascular shunts informs on the cellular mechanisms of formation and resolution of arteriovenous malformations

Diagnostic and therapeutic dilemmas of asymptomatic intracranial AVMs: A case report and evidence-based review

The Role of Medical Management in Vascular Anomalies

Brain Arteriovenous Malformation Biology Relevant to Hemorrhage and Implication for Therapeutic Development

Emerging pathogenic mechanisms in human brain arteriovenous malformations: a contemporary review in the multiomics era

Treatment of Challenging Extracranial Arteriovenous Malformations